XML 20 R9.htm IDEA: XBRL DOCUMENT v3.26.3
Public Offering
9 Months Ended
Sep. 30, 2026
Public Offering  
Public Offering

Note 3. Public Offering

2025 Public Offering

On January 6, 2025, the Company entered into an underwriting agreement with Aegis Capital Corp. (“Aegis” or the “Underwriter”) pursuant to which the Company agreed to sell and issue, in an underwritten public offering (the “2025 Offering”), 555,571 units, each consisting of (i) one (1) share of common stock, (ii) one (1) Series A Registered common warrant to purchase one (1) share of common stock per warrant (the “Series A Warrant”) at an exercise price of $45.00 (the “Exercise Price”) and (iii) one (1) Series B Registered common warrant to purchase one (1) share of common stock per warrant (the “Series B Warrant”) at an Exercise Price of $45.00. The closing of the 2025 Offering occurred on January 7, 2025. The Company received net proceeds of approximately $18.3 million from the 2025 Offering, after deducting the offering expenses payable by the Company, including the Underwriter’s fees and expenses.

The Series A Warrants were exercisable beginning on February 24, 2025, the date of approval by stockholders of the Company (the “Stockholder Approval Date” or the “Initial Exercise Date”), and expire in February 2030, the sixty (60) month anniversary of the Initial Exercise Date. The Series B Warrants were exercisable beginning on the Initial Exercise Date and expire in August 2027, on the thirty (30) month anniversary of the Initial Exercise Date.

Upon issuance, the Series A Warrants and Series B Warrants had an initial exercise price of $45.00, which was reset on the eleventh trading day after the Stockholder Approval Date (the “Reset Date”). Prior to the Stockholder Approval Date, the Series A Warrants and Series B Warrants had a floor price of $20.23, and following stockholder approval, the Series A Warrants and Series B Warrants had a floor price of $8.06. The reset price was the greater of (i) the lowest single trading day volume-weighted average price (“VWAP”) of the Company’s common stock during the reset period and (ii) the floor price, as defined in the agreement. The stock price on the Reset Date was below the floor price following the Stockholder Approval Date, and as such, the exercise price was reset to $8.06.

Additionally, the Company granted Aegis a 45-day option to purchase additional shares of common stock and/or Series A Warrants and Series B Warrants of (i) up to 15.0% of the number of shares of common stock sold in the offering, (ii) up to 15.0% of

the number of Series A Warrants sold in the offering and (iii) up to 15.0% of the number of Series B Warrants sold in the offering. The purchase price per additional share of common stock is equal to the public offering price of one unit (less $0.01 allocated to each full Series A Warrant and Series B Warrant), less the underwriting discount. The purchase price per additional Series A Warrant or Series B Warrant is $0.01. On January 7, 2025, Aegis exercised its over-allotment option with respect to 83,334 Series A Warrants and 83,334 Series B Warrants.

The holders of Series A Warrants can effect a cashless exercise if there is no effective registration statement at the time of exercise. The number of common shares to be issued would be calculated as VWAP minus exercise price of the Series A Warrants multiplied by the number of Series A Warrants to be cashlessly exercised. The holders of Series B Warrants may effect an alternative cashless exercise whether or not an effective registration statement is available for the issuance of shares. In such event, the number of shares to be issued would be calculated as the number of Series B Warrants multiplied by a factor of 3.0.

There were no exercises of Series A Warrants and Series B Warrants during the three and nine months ended September 30, 2026. During the nine months ended September 30, 2025, there were 3,438,095 Series B Warrants exercised in accordance with the alternative cashless exercise provision, resulting in the issuance of 10,314,285 shares of common stock. There were no exercises of Series B Warrants for the three months ended September 30, 2025. The fair value of the Series B Warrants exercised on the respective exercise dates for the nine months ended September 30, 2025 was $6.9 million. There were no Series A Warrants exercised during the three and nine months ended September 30, 2025. As of September 30, 2026, there were 3,565,245 Series A Warrants and 62,263 Series B Warrants outstanding.

The Company recognized a loss on issuance of warrants in the first quarter of 2025 of $75.6 million, which reflects the fair value of the Series A Warrants and Series B Warrants in excess of the proceeds received. For the three and nine months ended September 30, 2026 and 2025, the Company recognized $1.1 million, $2.3 million, $(0.2) million and $18.6 million, respectively, of income (expense) related to the change in fair value of the outstanding Series A Warrants, and $0.1 million, $0.1 million, de minimis and $7.9 million, respectively, of income (expense) related to the change in fair value of the remaining outstanding Series B Warrants. Refer to Note 6 Fair Value Measurements for additional information.

2026 Public Offering

On July 13, 2026, the Company entered into the Underwriting Agreement with the Representative, relating to the Company’s 2026 Offering of (i) 17,851,599 shares of common stock at a combined public offering price of $0.3221 per share and accompanying Milestone Warrants (as defined below) and (ii) 2026 Pre-Funded Warrants to purchase 24,837,008 shares of common stock at a combined public offering price of $0.3220 per 2026 Pre-Funded Warrant and accompanying Milestone Warrants. Each share of common stock and each 2026 Pre-Funded Warrant was accompanied by one Two-Year Milestone Warrant and one Five-Year Milestone Warrant, representing 200% aggregate warrant coverage. The 2026 Offering closed on July 15, 2026.

The Company granted the underwriters a 30-day option to purchase up to an additional 6,403,290 shares of common stock and/or 2026 Pre-Funded Warrants and up to 6,403,290 additional Two-Year Milestone Warrants and 6,403,290 additional Five-Year Milestone Warrants, in each case solely to cover over-allotments. On July 14, 2026, the underwriters exercised the option with respect to 6,403,290 Two-Year Milestone Warrants and 6,403,290 Five-Year Milestone Warrants, and on July 21, 2026, the underwriters exercised the option with respect to 4,696,102 shares of common stock. The remaining portion of the option expired unexercised on August 12, 2026. In total, the Company issued 22,547,701 shares of common stock, 24,837,008 2026 Pre-Funded Warrants, 49,091,897 Two-Year Milestone Warrants and 49,091,897 Five-Year Milestone Warrants. Aggregate gross proceeds were $15.3 million. Net proceeds were $13.7 million, after deducting direct and incremental issuance costs.

The 2026 Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately upon issuance and have no expiration date. The Two-Year Milestone Warrants have an exercise price of $0.3221 per share and expire on the earlier of July 15, 2028 and the 45th day following the Company’s public announcement that it has received Type 2b meeting minutes from the FDA that do not preclude advancement of ABP-450 toward a BLA under the Section 351(k) biosimilar pathway. The Five-Year Milestone Warrants have an exercise price of $0.3704 per share and expire on the earlier of July 15, 2031 and the 45th day following the Company’s public announcement that it has initiated a Phase 3 clinical equivalence trial of ABP-450 as a biosimilar to BOTOX®. At the option of the holder, each Milestone Warrant may be exercised for either one share of common stock or one pre-funded warrant in lieu thereof (at an exercise price of $0.3220 or $0.3703, respectively).

The Company evaluated the 2026 Pre-Funded Warrants and the Milestone Warrants under ASC 480 and ASC 815-40, Contracts in Entity’s Own Equity. The Company concluded that each of these instruments is a freestanding financial instrument that is not within the scope of ASC 480, is indexed to the Company’s own common stock, and meets the conditions for equity classification. Accordingly, the 2026 Pre-Funded Warrants and the Milestone Warrants are classified within stockholders’ equity and are not subject to subsequent remeasurement. The gross proceeds of the 2026 Offering were recorded in stockholders’ equity, and the direct and incremental issuance costs of $1.5 million were recorded as a reduction of additional paid-in capital.

On September 30, 2026, the Company announced that it had received Type 2b meeting minutes from the FDA that do not preclude advancement of ABP-450 toward a BLA under the Section 351(k) biosimilar pathway, which accelerated the expiration date of the Two-Year Milestone Warrants from July 15, 2028 to November 16, 2026. The Five-Year Milestone Warrants were not affected by the announcement. If the Two-Year Milestone Warrants expire unexercised, the Company will not receive the related exercise proceeds of up to approximately $15.8 million. On November 2, 2026, the Two-Year Milestone Warrants were amended. Refer to Note 10 Subsequent Events for more information.

During the three months ended September 30, 2026, holders exercised 4,913,878 2026 Pre-Funded Warrants for cash at $0.0001 per share, resulting in the issuance of 4,913,878 shares of common stock. No Milestone Warrants were exercised.

The table below summarizes the Milestone Warrants outstanding as of September 30, 2026:

​

​

​

​

​

Warrants outstanding

Shares

​

Exercise price

Expiration

Two-year milestone warrants

49,091,897

$

0.3221

November 16, 2026 (accelerated)

Five-year milestone warrants

49,091,897

$

0.3704

July 15, 2031, subject to earlier termination

Pre-funded warrants (July 2026 offering)

19,923,130

$

0.0001

None

​